- Home
- SGU vs PRTC Comparison
SGU vs PRTC Comparison
Compare SGU & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- PRTC
- Stock Information
- Founded
- SGU 1995
- PRTC 2015
- Country
- SGU United States
- PRTC United States
- Employees
- SGU N/A
- PRTC N/A
- Industry
- SGU Other Specialty Stores
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- SGU Consumer Discretionary
- PRTC Health Care
- Exchange
- SGU Nasdaq
- PRTC Nasdaq
- Market Cap
- SGU 445.9M
- PRTC 413.5M
- IPO Year
- SGU 1995
- PRTC N/A
- Fundamental
- Price
- SGU $11.75
- PRTC $17.80
- Analyst Decision
- SGU
- PRTC Buy
- Analyst Count
- SGU 0
- PRTC 1
- Target Price
- SGU N/A
- PRTC $45.00
- AVG Volume (30 Days)
- SGU 33.5K
- PRTC 5.3K
- Earning Date
- SGU 07-30-2025
- PRTC 08-27-2025
- Dividend Yield
- SGU 6.27%
- PRTC N/A
- EPS Growth
- SGU 123.45
- PRTC N/A
- EPS
- SGU 1.78
- PRTC 0.21
- Revenue
- SGU $1,803,079,000.00
- PRTC $4,828,000.00
- Revenue This Year
- SGU N/A
- PRTC $35.98
- Revenue Next Year
- SGU N/A
- PRTC $115.38
- P/E Ratio
- SGU $6.67
- PRTC $7.93
- Revenue Growth
- SGU 2.38
- PRTC 44.98
- 52 Week Low
- SGU $10.11
- PRTC $13.30
- 52 Week High
- SGU $13.75
- PRTC $25.00
- Technical
- Relative Strength Index (RSI)
- SGU 49.61
- PRTC 48.68
- Support Level
- SGU $11.63
- PRTC $17.48
- Resistance Level
- SGU $11.92
- PRTC $18.30
- Average True Range (ATR)
- SGU 0.22
- PRTC 0.45
- MACD
- SGU 0.04
- PRTC 0.02
- Stochastic Oscillator
- SGU 80.47
- PRTC 68.48
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.